Disease-modifying therapies in systemic lupus erythematosus for ...
WebMay 22, 2024 · In this review, we further explore the concept of disease modification in SLE by applying the proposed criteria to treatments currently used in SLE, where the assessment of treatment tolerability is excluded and the focus is on disease activity and irreversible organ damage criteria.
Disease-modifying therapies in systemic lupus erythematosus for ...
WebMay 22, 2024 · PMID: 38777595. DOI: 10.1136/lupus-2023-001124. Abstract. Our 2022 published working definition of disease modification in systemic lupus erythematosus (SLE) was 'minimising disease activity with the fewest treatment-associated toxicities and slowing or preventing organ damage progression'.
Systemic lupus erythematosus (CNS manifestations)
WebMay 7, 2024 · movement disorders are rarely described in association with SLE 3-5. it is thought that infarction or neuronal antibodies may play a role in the etiology of these movement disorders in SLE 3-5
(READ) FDA approves new drug for autoimmune lupus disorder SLE
WebMay 25, 2024 · By Sharyl Attkisson | August 21, 2021. The FDA has approved a new drug from Astra Zeneca to treat some patients with systemic lupus erythematosus (SLE). It’s the first approved drug of its kind, and the only new treatment for SLE in more than a decade, according to Astra Zeneca.
Different SLE symptoms are driven by combinations of immune...
WebMay 20, 2024 · Different combinations and elevated levels of antiviral immune signaling proteins, called interferons (IFNs), were associated with differences in the symptoms and severity of systemic lupus erythematosus (SLE), a study shows. While IFNs are known to play a role in the disease, increases in IFN levels don ‘t explain many common SLE …
Efficacy and safety study of targeted small-molecule drugs in the ...
WebMay 10, 2024 · Targeted small-molecule drugs in the treatment of systemic lupus erythematosus (SLE) have attracted increasing attention from clinical investigators. However, there is still a lack of evidence on the difference in the efficacy and safety of different targeted small-molecule drugs.
Unraveling transcriptomic signatures and dysregulated pathways …
WebMay 13, 2024 · Gene signatures. This study aims to elucidate the transcriptomic signatures and dysregulated pathways in patients with Systemic Lupus Erythematosus (SLE), with a particular focus on those persisting during disease remission.
Lupus - Wikipedia
WebMay 26, 2024 · Lupus, technically known as systemic lupus erythematosus ( SLE ), is an autoimmune disease in which the body's immune system mistakenly attacks healthy tissue in many parts of the body. [1] . Symptoms vary …
Pediatric Systemic Lupus Erythematosus - Medscape
Web6 days ago · Systemic lupus erythematosus (SLE) is a rheumatic disease characterized by autoantibodies directed against self-antigens, immune complex formation, and immune dysregulation, resulting in...
Systemic Lupus Erythematosus | Medscape
WebMay 14, 2024 · Systemic Lupus Erythematosus : Review in-depth clinical information, latest medical news, and guidelines on lupus, systemic lupus erythematosus (SLE). Recognize lupus symptoms and signs of lupus.
Skip to content